We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Authorization

News List

I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million prnasia
July 16, 2020
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors has authorized a stock repurchase program under
Mylan, Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization for Hulio americanpharmaceuticalreview
September 21, 2018
Mylan and Fujifilm Kyowa Kirin Biologics announced the European Commission (EC) has granted marketing authorization for Hulio, a biosimilar to AbbVie's Humira (adalimumab), for all indications.
Initial Pre-Emergency Use Authorization Submission Made to U.S. FDA for Use of ReCell in a Mass Casu americanpharmaceuticalreview
May 11, 2017
Avita Medical received notification of the initial FDA review of the Pre-EUA (Emergency Use Authorization) submission to allow the emergency deployment of its ReCell device for a mass casualty event involving burn injuries.